youtube_live
Q3 2026 earnings • in 3 days
See detailschevron_right
TXG:NASDAQ
10X Genomics Inc
$61.63
arrow_downward
-12.10%(-8.48) 1D
$61.66
arrow_upward
+0.05% (+0.031)bedtimeAfter hours
Closed: Nov 2, 4:00:00 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TXG...
Open
$70.31
High
$71.00
Low
$61.24
Mkt. cap
8.03B
Avg. vol.
3.86M
Volume
0.00
52-wk high
$102.81
52-wk low
$12.80
EPS
-$0.59
Beta
1.99
Shares outstanding
120.21M
No. of employees
1K
Open
$70.31
High
$71.00
Low
$61.24
Mkt. cap
8.03B
Avg. vol.
3.86M
Volume
0.00
52-wk high
$102.81
52-wk low
$12.80
EPS
-$0.59
Beta
1.99
Shares outstanding
120.21M
No. of employees
1K
News stories
From web sources and news partners
Yahoo Finance
·
9 hours ago
10x Genomics Sinks 12%, Twist Down 15%, PacBio Down 10% as Genomics Stocks Give Back Rebound
Finimize
·
10 hours ago
AI Tools And Trial Stops Split Healthcare Stocks
Investing.com
·
15 hours ago
10x Genomics launches AI-powered single cell analysis tool
Profile
10x Genomics, Inc. is an American biotechnology company that designs and manufactures sequencing technologies for use in scientific research, with a focus on product development for single-cell and spatial omics. Wikipedia
About 10X Genomics Inc
CEOSerge Saxonov
Employees1.18K
Founded2012
HeadquartersPleasanton, California, United States
SectorHealth care
Website10xgenomics.com
Analyst ratings
Based on 16 analysts giving stock ratings to TXG in the past 3 months
Buy
Buy
6
Hold
10
Sell
0
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for TXG in the last 3 months.
Highest
Current $61.63
$110.00 (+78.48%)
Average
$75.73 (+22.88%)
Lowest
$50.00 (-18.87%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Mason Carrico Stephens | Hold | Downgraded | $65.00 | +5.5% | 10/23/2026 |
Casey Woodring J.P. Morgan | Hold | Maintained | $70.00 | +13.6% | 10/16/2026 |
Daniel Brennan TD Cowen | Hold | Maintained | $70.00 | +13.6% | 10/13/2026 |
Kallum Titchmarsh Morgan Stanley | Hold | Reiterated | $70.00 | +13.6% | 10/13/2026 |
Kyle Mikson CFA Canaccord Genuity | Buy | Maintained | $100.00 | +62.3% | 10/12/2026 |
Avantika Dhabaria Bank of America Securities | Hold | Maintained | $80.00 | +29.8% | 10/09/2026 |
Michael Ryskin Bank of America Securities | Hold | Maintained | $80.00 | +29.8% | 10/09/2026 |
Luke Sergott Barclays | Buy | Maintained | $110.00 | +78.5% | 10/07/2026 |
Matt Larew William Blair | Buy | Maintained | - | - | 09/29/2026 |
Puneet Souda Leerink Partners | Hold | Maintained | $90.00 | +46% | 09/29/2026 |
David Westenberg Piper Sandler | Hold | Reiterated | $80.00 | +29.8% | 09/28/2026 |
Unknown Analyst Argus Research | Buy | Initiated | $110.00 | +78.5% | 09/28/2026 |
John Eade Argus Research | Buy | Initiated | $110.00 | +78.5% | 09/25/2026 |
Unknown Analyst UBS | Hold | Initiated | $68.00 | +10.3% | 09/08/2026 |
Doug Schenkel UBS | Hold | Maintained | $68.00 | +10.3% | 09/09/2026 |
Dan Leonard RBC Capital | Hold | Initiated | $70.00 | +13.6% | 09/01/2026 |
Unknown Analyst Stephens | Buy | Reiterated | $65.00 | +5.5% | 08/12/2026 |
Daniel Arias Stifel Nicolaus | Buy | Maintained | $50.00 | -18.9% | 08/11/2026 |
Tycho Peterson Jefferies | Buy | Reiterated | $53.00 | -14% | 08/07/2026 |
Patrick B Donnelly Citi | Hold | Maintained | $50.00 | -18.9% | 08/07/2026 |
Brendan Digan Citi | Hold | Maintained | $50.00 | -18.9% | 08/07/2026 |
Justin Bowers Deutsche Bank | Hold | Maintained | $23.00 | -62.7% | 05/08/2026 |
Next call in 3 days
Thu, Nov 5, 4:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$0.02
Revenue / Est. (USD)
- / 147.85M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 149.00M | 166.03M | 150.84M | 151.04M |
Cost of goods sold | 48.70M | 52.88M | 44.66M | 38.54M |
Cost of revenue | 48.70M | 52.88M | 44.66M | 38.54M |
Research and development expenses | 57.19M | 55.77M | 56.85M | 56.79M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 74.66M | 73.02M | 66.38M | 78.66M |
Operating expense | 131.85M | 128.79M | 123.22M | 135.45M |
Total operating expenses | 180.54M | 181.67M | 167.89M | 173.99M |
Operating income | -31.54M | -15.64M | -17.05M | -22.96M |
Other non operating income | 538.00K | -3.04M | -72.00K | -3.49M |
EBT including unusual items | -28.20M | -15.19M | -12.85M | -18.64M |
EBT excluding unusual items | -26.40M | -12.39M | -12.90M | -22.04M |
Income tax expense | -733.00K | 1.06M | 623.00K | -714.00K |
Effective tax rate | 2.60% | -6.97% | -4.85% | 3.83% |
Other operating expenses | - | - | - | - |
Net income | -27.47M | -16.25M | -13.47M | -17.93M |
Net profit margin | -18.44% | -9.79% | -8.93% | -11.87% |
Earnings per share | -0.02 | 0.07 | 0.07 | 0.03 |
Interest and investment income | 5.20M | 6.89M | 5.01M | 4.80M |
Interest expense | - | - | - | - |
Net interest expenses | 5.20M | 6.89M | 5.01M | 4.80M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -21.24M | -5.58M | -7.09M | -13.29M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events